Johnson & Johnson Stock News

Johnson & Johnson (NYSE:JNJ), the healthcare group, raised its 2026 sales and earnings forecasts after third-quarter sales grew 6% on an operational basis, supported by its medicines business and new products. The company increased its estimated full-year reported sales midpoint to $101.2 billion from $101.1 billion, implying growth of 7.4%, and raised its adjusted earnings per share (EPS) midp...

Johnson & Johnson stock fell early Tuesday as the conflict in the Middle East weighted on medical device sales.

Johnson & Johnson ⁠reported a slightly higher-than-expected profit on Tuesday, driven by strong sales of immune disease treatment Tremfya, but geopolitical issues, including the Middle East conflict, were a drag on its medical devices business. Shares fell more than 2% before the bell.

Johnson & Johnson says it is working to improve results in its medical-device business, where surgery revenue fell for the latest quarter.

Johnson & Johnson is “leaning” toward spinning out the hips-and-knees business that the company has been looking to hive off, Chief Financial Officer Joseph Wolk said.

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2026 of $1.34 per share on the company's common stock. The dividend is payable on December 8, 2026 to shareholders of record at the close of business on November 24, 2026. The ex-dividend date is November 24, 2026. About Johnson &...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2026. “Johnson & Johnson's strong third-quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio,” said Joaquin Duato, Chairman and Chief Executive Officer. “In the third quarter, we advanced breakthroughs that will redefine care for...